A Trial Of SU14813 In Patients With Advanced Solid Malignancies

A Phase I Dose Escalating Study Of SU014813 In Patients With Solid Tumors Not Amenable To Conventional Therapy

The purpose of this study is to define the Maximum tolerated dose of SU14813 when administered as single agent in patients with solid tumors.

Inclusion Criteria:

• Patients with a histologically proven advanced solid malignancy for which no recognized therapy was available or for which standard therapy had failed
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Serum albumin ≥3.0 g/dL and adequate haemopoietic, renal and liver function

Exclusion Criteria:

• Chemotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) or radiotherapy or an investigational agent within 4 weeks before the start of study treatment
• Subjects had to have recovered from all prior treatment toxicities, except alopecia, and from any major surgery.